Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma Source: Annual Congress 2010 - Allergy and risk factors in paediatrics Year: 2010
Evaluation of efficacy and safety of budesonide/formeterol combination therapy in asthma patients Source: Eur Respir J 2006; 28: Suppl. 50, 314s Year: 2006
Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019 Year: 2020
Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma Source: Eur Respir J, 55 (1) 1901147; 10.1183/13993003.01147-2019 Year: 2020
Efficacy and safety of long-term therapy with Salamol combined with Beclason versus Salamol only in patients with mild persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 42s Year: 2002
The effectiveness of inhaled steroids as first-line therapy in the treatment of newly detected asthma Source: Eur Respir J 2001; 18: Suppl. 33, 266s Year: 2001
Asthma and once-daily administration of inhaled corticosteroids: potential for improved compliance and reduced health costs Source: Eur Respir J 2002; 20: Suppl. 38, 305s Year: 2002
Comparative effectiveness of two different doses of inhaled corticosteroid in triple therapy on exacerbations in patients with severe COPD: a real-world study Source: Virtual Congress 2021 – Therapies for respiratory diseases in primary care and COVID - 19 Year: 2021
Long-term treatment of aspirin-intolerante asthma with budesonide. Effectivity and safety Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
The safety of LAMA/LABA combination therapy for the ocular and urinary adverse effects in the COPD patients Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019
An economic evaluation of adding inhaled corticosteroids to systemic corticosteroids for treating acute asthma exacerbations Source: International Congress 2019 – Severe acute asthma and troublesome wheezing Year: 2019
Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids Source: Breathe 2010; 6: 365 Year: 2010
Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Efficacy of systemic corticosteroids in refractory asthmatics showing no bronchial reversibility with high-dose inhaled corticosteroids or β2 agonist inhalation Source: Annual Congress 2010 - Clinical aspects and treatment of asthma and allergic respiratory diseases Year: 2010
Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma Source: Eur Respir J, 53 (2) 1800948; 10.1183/13993003.00948-2018 Year: 2019
Integrating high dose inhaled corticosteroids into oral corticosteroids stewardship Source: Eur Respir J, 55 (1) 1902193; 10.1183/13993003.02193-2019 Year: 2020
Evaluating the efficacy of chronic therapy with tiotropium in COPD through discontinuation of treatment Source: Eur Respir J 2002; 20: Suppl. 38, 245s Year: 2002
Nebulizer therapy with budesonide in addition to systemic corticosteroids in acute severe asthma Source: Eur Respir J 2004; 24: Suppl. 48, 541s Year: 2004
Regular use of inhaled corticosteroids and the long-term prevention of hospitalisation for asthma Source: Eur Respir J 2002; 20: Suppl. 38, 8s Year: 2002
Reducing the dose of inhaled corticosteroids (ICS) under therapy with montelukast in stable asthma: effects on lung function and inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 261s Year: 2001